Mar 08, 2022 / 03:30PM GMT
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good morning. I'd like to welcome Eli Lilly to Cowen's 42nd Annual Healthcare Conference. We're very, very pleased to have Lilly back with us again this year. Let me say that Cowen is recommending Eli Lilly stock because we see above-average growth driven by differentiated new products, which has been a feature of Lilly for virtually 10 years, if not more. So exciting situation that we think investors should be participating in.
So representing the company is Anat Ashkenazi, who is the CFO of the company. So Anat, thank you so much for being with us today.
Questions and Answers:
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystI'd like to start out with one of the most exciting developments that will occur in 2022, and that is tirzepatide. And I'm curious, is Lilly ready to launch immediately post-approval? Or will it depend on what the label says and some time will be needed to train the sales
Trustpilot
